Bringing immunoglobulin knowledge up to date: How should we treat today?

Clinical and Experimental Immunology

Volumn 166, Issue 1, 2011, Pages 16-25

  Misbah, Siraj ^a   Kuijpers, T ^b   van der Heijden, J ^b   Grimbacher, B ^c   Guzman, D ^c   Orange, J ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IgG receptor; Immunoglobulin; Intravenous IgG; Primary immunodeficiencies; Subcutaneous IgG

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; AUTOIMMUNE NEUROPATHY; DRUG RESEARCH; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; PRIMARY ANTIBODY DEFICIENCY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

C-REACTIVE PROTEIN; CONGRESSES AS TOPIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; META-ANALYSIS AS TOPIC; RECEPTORS, IGG;

EID: 80052615449     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04443.x     Document Type: Article

References (45)

1. Yong PL, Boyle J, Ballow M etal. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010; 135:255-63.
2. Hagan JB, Fasano MB, Spector S etal. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734-45.
3. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265-73.
4. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
5. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-60.
6. Halliday E, Winkelstein J, Webster AD. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Infect 2003; 46:1-8.
7. ® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011; doi: 10.1016/j.clim.2011.06.002.
8. Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155:147-55.
9. Wasserman RL, Melamed I, Nelson RP, Jr etal. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinetics 2011; 50:405-14.
10. Aghamohammadi A, Moin M, Farhoudi A etal. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004; 40:113-18.
11. Foy HM, Cooney MK, Allan I, Kenny GE. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979; 241:253-8.
12. Jokinen C, Heiskanen L, Juvonen H etal. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137:977-88.
13. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1:671-4.
14. Eades-Perner AM, Gathmann B, Knerr V etal. The European internet-based patient and research database for primary immunodeficiencies: results 2004-06. Clin Exp Immunol 2007; 147:306-12.
15. Roifman CM, Schroeder H, Berger M etal. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3:1325-33.
16. de Gracia J, Vendrell M, Alvarez A etal. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4:745-53.
17. Mazer BD, Gelfand EW. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87:976-83.
18. Kainulainen L, Varpula M, Liippo K, Svedstrom E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 1999; 104:1031-6.
19. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM 2002; 95:655-62.
20. Martinez Garcia MA, Hernandez F, de Rojas MD etal. Respiratory disorders in common variable immunodeficiency. Respir Med 2001; 95:191-5.
21. Smith RP, Lipworth BJ. C-reactive protein in simple community-acquired pneumonia. Chest 1995; 107:1028-31.
22. Corsonello A, Pedone C, Battaglia S, Paglino G, Bellia V, Incalzi RA. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammation markers in elderly patients with stable chronic obstructive pulmonary disease (COPD). Arch Gerontol Geriatr 2010; doi: 10.1016/j.archger.2010.10.015. Epub ahead of print.
23. Miedema KG, de Bont ES, Elferink RF etal. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 2010; doi: 10.1007/s00520-010-0987-6. Epub ahead of print.
24. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94-100.
25. Gardulf A, Nicolay U, Asensio O etal. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26:177-85.
26. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:1-7.
27. Thepot S, Malphettes M, Gardeur A etal. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30:602-6.
28. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009; 16:631-8.
29. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009; 14:93-100.
30. Misbah S, Baumann A, Fazio R etal. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011; 16:92-7.
31. Tayal U, Burton J, Dash C, Wojnarowska F, Chapel H. Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita. Clin Immunol 2008; 129:518-19.
32. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010; 30:301-7.
33. Willcocks LC, Lyons PA, Clatworthy MR etal. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008; 205:1573-82.
34. Aitman TJ, Dong R, Vyse TJ etal. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851-5.
35. Breunis WB, van Mirre E, Bruin M etal. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008; 111:1029-38.
36. de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE. Neutrophil Fc gamma RIIIb deficiency, nature, and clinical consequences: a study of 21 individuals from 14 families. Blood 1995; 86:2403-13.
37. Koene HR, Kleijer M, Roos D, de Haas M, von dem Borne AE. Fc gamma RIIIB gene duplication: evidence for presence and expression of three distinct Fc gamma RIIIB genes in NA(1+, 2+)SH(+) individuals. Blood 1998; 91:673-9.
38. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009; 157:244-54.
39. Redon R, Ishikawa S, Fitch KR etal. Global variation in copy number in the human genome. Nature 2006; 444:444-54.
40. Breunis WB, van Mirre E, Geissler J etal. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009; 30:E640-50.
41. Huizinga TW, Kuijpers RW, Kleijer M etal. Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood 1990; 76:1927-32.
42. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. 2007: 715-25.
43. Petkova SB, Akilesh S, Sproule TJ etal. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69.
44. Hughes RA, Donofrio P, Bril V etal. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7:136-44.
45. Khan S, Grimbacher B, Boecking C etal. Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. Drug Metab Lett 2011; 5:132-6.